Microbot Medical Secures Major Government Sales Channel for LIBERTY Robotic System
Summary
Microbot Medical has partnered with Lovell Government Services to sell its LIBERTY Endovascular Robotic System to over 2,000 U.S. government facilities, significantly expanding its market reach.
Key Events
-
New Government Sales Agreement
Microbot Medical entered into a vendor agreement with Lovell Government Services to expand the sales reach of its LIBERTY Endovascular Robotic System.
-
Expanded Market Access
The agreement creates opportunities to sell the LIBERTY System at more than 2,000 U.S. government facilities, including those administered by the U.S. Department of Veterans Affairs, the Department of Defense, and the U.S. Indian Health Service.
-
Streamlined Procurement
Lovell Government Services will serve as the company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, facilitating sales through federal contracting systems like the Federal Supply Schedule (FSS), GSA Advantage, and ECAT.
-
Q3 2026 Activation Expected
The LIBERTY System is expected to be added to Lovell's Federal Supply Schedule (FSS) contract, with activation anticipated during the third quarter of 2026.
Analysis
Microbot Medical has established a critical partnership with Lovell Government Services, opening access to over 2,000 U.S. government healthcare facilities for its LIBERTY Endovascular Robotic System. This agreement is a significant step in the company's commercialization strategy, providing a streamlined procurement pathway through federal contracts and potentially boosting revenue as the company navigates initial losses and cash burn.
At the time of this filing, MBOT was trading at $1.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $122.2M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.